INTRODUCTION {#s1}
============

Lung cancer is one of the most common malignancies and the most frequent cause of cancer-related mortality worldwide \[[@R1]\]. Despite the significant improvement in chemotherapy regimen for the treatment of advanced non-small-cell lung cancer (NSCLC), the 5-year survival for these patients remains relative poor \[[@R2], [@R3]\]. Thus, novel agents are urgently needed to improve the prognosis of these patients.

The epidermal growth factor receptor (EGFR) is a member of the HER family of receptor tyrosine kinases which plays a critical role in regulating the development and progression of many solid tumors including NSCLC \[[@R4]--[@R6]\]. Thus, EGFR and its related signal pathway have been regarded as attractive therapeutic targets in the treatment of NSCLC \[[@R7], [@R8]\]. Currently, three anti-EGFR agents, gefitinib, erlotinib and afatinib have been approved for use in EGFR mutation-positive NSCLC patients \[[@R9], [@R10]\]. Although EGFR-TKIs are generally well tolerated, a pattern of adverse events such as skin rash, diarrhea, thromboembolic events and interstitial lung disease have been reported \[[@R11]--[@R15]\], which is different from traditional cytotoxic agents. Infections have been reported with anti-EGFR agents. In 2014, Qi et al. performed a meta-analysis and found a significantly increased risk of severe infectious events associated with the use of anti-EGFR mono-clonal antibodies cetuximab and panitumumab in cancer patients (RR 1.34, p = 0.003) \[[@R16]\]. However, whether EGFR-TKIs increase the risk of infections in NSCLC remains unknown. We thus perform this meta-analysis and systematic review of available randomized controlled trials to determine the overall incidence and risk of infections in NSCLC patients treated with these drugs.

RESULTS {#s2}
=======

Search results {#s2_1}
--------------

We identified a total of 362 related studies through the database search, and retrieved 52 full-text studies for evaluation. The reasons for study exclusion were illustrated in Figure [1](#F1){ref-type="fig"}. As a result, 25 RCTs with 13,436 patients were included for the present study \[[@R17]--[@R41]\]. The baseline characteristics of each trial were presented in Table [1](#T1){ref-type="table"}. For the indications of the included studies, there were eight trials in first-line settings, two trials in adjuvant settings, and fifteen trials in the subsequent lines of treatment (maintenance or second line, Table [1](#T1){ref-type="table"}). An open assessment of the included trials was carried out by using Jadad scale, and fourteen trials were placebo-controlled, double-blinded randomized trials with Jadad score of 5, and eleven trials had Jadad scores of 3.

![Studies eligible for inclusion in the meta-analysis](oncotarget-08-29406-g001){#F1}

###### baseline characteristics of 25 trials Included in the Meta-analysis (*n*=17,420)

  Studies                                   Treatment strategy    Enrolled patients (n)   Treatment arms                             Median age (years)   Median EGFR-TKIs duration (months)   Median PFS/TTP (months)   Median OS (months)   Patients for analysis   Severe infections   Reported infectious events
  ----------------------------------------- --------------------- ----------------------- ------------------------------------------ -------------------- ------------------------------------ ------------------------- -------------------- ----------------------- ------------------- -------------------------------------------------------
  Herbst R.S. et al 2004 (INTACT-2)         First-line            1037                    Gefitinib 500mg/d plus PC                  62                   99 days                              4.6                       8.7                  342                     NR                  Pneumonia, sepsis
                                                                                          Gefitinib 250mg/d plus PC                  61                   129 days                             5.3                       9.8                  342                     NR                  
                                                                                          Placebo plus PC                            63                   138 days                             5.0                       9.9                  341                     NR                  
  Giaccone G. et al 2004 (INTACT-1)         First-line            1093                    Gefitinib 500mg/d plus GD                  61                   97d                                  5.5                       9.9                  358                     NR                  Pneumonia
                                                                                          Gefitinib 250mg/d plus GD                  59                   150d                                 5.8                       9.9                  362                     NR                  
                                                                                          Placebo plus GD                            61                   159d                                 6.0                       10.9                 355                     NR                  
  Herbst R.S. et al 2005 (TRIBUTE)          First-line            1059                    Erlotinib 150mg/d plus PC                  62.7                 4.6m                                 5.1                       10.6                 526                     15                  Febrile neutropenia, Pneumonias, sepsis, septic shock
                                                                                          Placebo plus PC                            62.6                 5.3m                                 4.9                       10.5                 533                     7                   
  Shepherd F.A. et al 2005                  Salvage treatment     731                     Erlotinib 150mg/d                          62                   NR                                   2.2                       6.7                  485                     2                   Infection, pneumonitis
                                                                                          Placebo                                    59                   NR                                   1.8                       4.7                  242                     5                   
  Thatcher N. et al 2007                    Salvage treatment     1692                    Gefitinib 250mg plus BSC                   62                   2.9                                  3.0                       5.6                  1126                    30                  Pneumonia
                                                                                          Placebo 250mg plus BSC                     61                   2.7                                  2.6                       5.1                  562                     15                  
  Galzemeier U. et al 2007                  First-line            1172                    Erlotinib 150mg/d plus GD                  60.0                 NR                                   23.7 weeks                43 weeks             579                     NR                  Neutropenia/febrile neutropenia/neutropenic sepsis
                                                                                          Placebo plus GD                            59.1                 NR                                   24.6 weeks                44.1 weeks           580                     NR                  
  Kelly K. et al 2008 (SWOG S0023)          Maintenance           243                     Gefitinib 250mg/d                          62                   NR                                   8.3                       23                   118                     3                   Pneumonitis
                                                                                          Placebo                                    61                   NR                                   11.7                      35                   125                     0                   
  Kim E.S. et al 2008 (INTEREST)            Second-line           1433                    Gefitinib 250mg/d                          61                   4.4                                  2.2                       7.6                  729                     23                  Lung infections
                                                                                          Docetaxel                                  60                   3.0                                  2.7                       8.0                  715                     25                  
  Cappuzzo F. et al/2010 (SATURN:BO18192)   Maintenance           1949                    Erlotinib 150mg qd po                      60                   NR                                   12.3weeks                 12                   433                     4                   Infections
                                                                                          Placebo                                    60                   NR                                   11.1weeks                 11                   445                     0                   
  Lee D.H. et al 2010 (ISTANA)              Second-line           161                     Gefitinib 250 mg/d                         57                   NR                                   3.3                       NR                   81                      NR                  Pneumonia, septic shock
                                                                                          Docetaxel                                  58                   NR                                   3.4                       NR                   76                      NR                  
  Maemondo M. et al 2010                    First-line            230                     Gefitinib 250mg/d                          63.9                 308 days                             10.8                      30.5                 114                     3                   Pneumonia
                                                                                          PC                                         62.6                 84 days                              5.4                       23.6                 114                     0                   
  Gaafar R.M. et al/2011 (EORTC 08021)      Maintenance           173                     Gefitinib 250mg/d                          61                   115d                                 4.1                       10.9                 85                      1                   Infections
                                                                                          Placebo                                    62                   85d                                  2.3                       9.4                  86                      1                   
  Natale R.B. et al 2011                    Second-line           1240                    Erlotinib 150 mg/d                         61                   8.6 weeks                            2.0                       7.8                  614                     NR                  Pneumonia, respiratory tract infection
                                                                                          Vandetanib 300mg/d                         61                   9.1 weeks                            2.6                       6.9                  623                     NR                  
  Zhou C. et al 2011 (OPTIMAL)              First-line            165                     Erlotinib 150mg/d                          57                   55.5 weeks                           13.1                      NR                   83                      1                   Infection
                                                                                          Gemcitabine plus carboplatin               59                   10.4 weeks                           4.6                       NR                   72                      0                   
  Ciuleanu T. et al 2012 (TITAN)            Second-line           424                     Erlotinib 150mg/d                          59                   NR                                   6.3 weeks                 5.3                  196                     1                   Infections
                                                                                          Chemotherapy                               59                   NR                                   8.6 weeks                 5.5                  213                     1                   
  Lee S.M. et al 2012 (TOPICAL)             First-line            670                     Erlotinib 150mg/d                          77                   NR                                   2.8                       3.7                  334                     5                   Pneumonia
                                                                                          Placebo                                    77                   NR                                   2.6                       3.6                  313                     1                   
  Perol M. et al. 2012                      Maintenance therapy   464                     Observation                                59.8                 10.9 weeks                           1.9                       10.8                 155                     0                   Infections
                                                                                          Gemcitabine                                57.9                 12 weeks                             3.8                       15.2                 154                     2                   
                                                                                          Erlotinib 150mg/d                          56.4                 12.1 weeks                           2.9                       11.4                 155                     4                   
  Rosell R. et al 2012 (EURTAC)             First-line            174                     Erlotinib 150mg/d                          65                   8.2                                  9.7                       19.3                 84                      1                   Pneumonitis
                                                                                          Chemotherapy                               65                   2.8                                  5.2                       19.5                 82                      1                   
  Sun J.M. et al 2012 (KCSG-LU08-01)        Second-line                                   Gefitinib 250mg/d                          58                   NR                                   9.0                       22.2                 68                      1                   Infections
                                                                                          Pemetrexed                                 64                   NR                                   3.0                       18.9                 67                      2                   
  Goss G.D. et al/2013 (NCIC CTG BR 19)     Adjuvant              503                     Gefitinib 150mg/d                          66                   NR                                   4.2y                      5.1y                 251                     7                   Infection, pneumonitis
                                                                                          Placebo                                    67                   NR                                   NR                        NR                   252                     3                   
  Johson B.E. et al 2013 (ATLAS)            Maintenance           1145                    Erlotinib 150mg/d+ bevacizumab             64                   72d                                  4.76                      14.39                368                     17                  Infection
                                                                                          Placebo +bevacizumab                       64                   64d                                  3.71                      13.31                367                     18                  
  Kawaguchi T. et al 2014 (DELTA)           Second-line           301                     Erlotinib                                  68                   NR                                   2.0                       14.8                 150                     2                   Pneumonitis
                                                                                          Docetaxel                                  67                   NR                                   3.2                       12.2                 150                     3                   
  Li N. et al 2014                          Second-line           123                     Erlotinib 150mg/d                          54.3                 NR                                   4.1                       11.7                 61                      0                   Infection
                                                                                          Pemetrexed                                 55.1                 NR                                   3.9                       13.4                 62                      0                   
  Kelly. K. et al 2015 (RADIANT)            Adjuvant              973                     Erlotinib 150mg/d                          62                   NR                                   46.4                      NR                   611                     8                   Pneumonia
                                                                                          Placebo                                    61                   NR                                   28.5                      NR                   343                     2                   
  Soria J.C. et al 2015 (IMPRESS)           Second-line           265                     Gefitinib 150mg/d+ Pemetrexed +cisplatin   60                   152.5d                               5.4                       14.8                 133                     NR                  Pneumonia
                                                                                          Placebo+ Pemetrexed +cisplatin             58                   161.5d                               5.4                       17.2                 132                     NR                  

Abbreviation: TXT, docetaxel; NA, not reported; PC, paclitaxel plus carboplatin; GP, gemcitabine plus cisplatin; BSC, best support care; GD, gemcitabine plus cisplatin; NR, not reported;

Overall incidence of infections {#s2_2}
-------------------------------

For the all-grade infectious incidence, a total of 6,593 patients were included for analysis. The pooled incidence was 7.0% (95%CI: 4.7-10.3%). For high-grade infections, a total of 5,977 patients were included for analysis yielding a pooled incidence 2.1% (95%CI: 1.7-2.8%). Additionally, 4,077 patients were included for fatal infections analysis. There was a total of 18 fatal infections reported yielding a pooled incidence of 0.7% (95%CI: 0.4% to 1.0%).

Peto Odds ratio of infections {#s2_3}
-----------------------------

In order to determine the specific contribution of EGFR-TKIs to the development of infections, a meta-analysis of the Peto OR of infections was performed. Our results showed that the Peto OR of all-grade infections was 1.48 (95%CI: 1.12-1.96, p = 0.006, Figure [2A](#F2){ref-type="fig"}), while the Peto OR of high-grade infections was 1.26 (95%CI: 0.96-1.67, p = 0.098, Figure [2B](#F2){ref-type="fig"}). Thus, the use of EGFR-TKIs in NSCLC patients had an increased risk of all-grade infections, but not for high-grade infections. Severe infections could be potentially life-threatening adverse events. There were 18 fatal infections events occurred in the EGFR-TKIs and 21 fatal infections events occurred in control arms, yielding a Peto OR 0.81 (95%CI: 0.43-1.53, p = 0.52, Figure [2C](#F2){ref-type="fig"}). No significant heterogeneity was found during the Peto OR analysis (Q = 6.64; P = 0.88; I2 = 0%). In addition, we conducted sub-group analysis based on treatment regimens, and demonstrated that the addition of EGFR-TKIs to chemotherapy had a tendency to increase the risk of infections in comparison with chemotherapy alone (Peto OR 1.24, 95%CI: 0.75-3.05, p = 0.39). Similarly, the use of EGFR-TKIs alone had a tendency to increase the risk of all-grade infections when compared to placebo (Peto OR 2.24, 95%CI: 0.27-18.53, p = 0.45) or chemotherapy alone (Peto OR 1.93, 95%CI: 0.88-4.26, p = 0.10). Finally, we carried out a meta-regression analysis to investigate the association between Peto OR of all-grade infections and the length of EGFR-TKIs treatment. The results showed that the longer EGFR-TKIs treatment, and the higher risk of infections with EGFR-TKIs, but this relationship was not statistically significant (P = 0.26, Figure [3](#F3){ref-type="fig"}).

![Risk of infections associated with EGFR-TKIs treatment compared with placebo treatment\
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![Meta-regression analysis of trends between treatment duration and relative risk of infections: symbols: each study is represented by a circle the diameter of which is proportional to its statistical weight](oncotarget-08-29406-g003){#F3}

Risk of specific infections {#s2_4}
---------------------------

We performed analysis to analyze the risk of all-grade infections based on specific type of infection. There was an increased risk of developing EGFR-TKIs-related infections (Peto OR 1.34, 95%CI: 1.08-1.66, p = 0.008) and febrile neutropenia (Peto OR 2.48, 95%CI: 1.31-4.69, p = 0.005), but not for pneumonia (Peto OR 0.97, 95%CI: 0.73-1.29, p = 0.82).

Publication bias {#s2_5}
----------------

Egger's test and Begg's test was used to detect publication bias. There was no evidence of publication bias for the primary endpoint of this meta-analysis (Peto OR of all-grade infections; Begg's test p = 0.12; Egger's test p = 0.06).

DISCUSSION {#s3}
==========

The introduction of novel targeted agents into the treatment of cancer has led to improve overall survival of many solid tumors. However, infection is an emerging complication with these drugs, and concerns have arisen regarding the potential risk of developing infections associated with targeted agents. Rafailidis et al \[[@R42]\] conducted the first systematic review in 2007 and demonstrated that there was an increased risk of developing monoclonal antibodies related severe infections but not for fatal adverse events. In consistent with previous results, two later meta-analyses also showed that EGFR-monoclonal antibodies significantly increased the risk of developing severe infections but not for fatal adverse events \[[@R16], [@R43]\]. Recently, Qi et al. performed another meta-analysis and showed that there was an increased risk of developing all-grade (RR 1.45, p \< 0.001) and high-grade (RR 1.59, p \< 0.001) infectious events in cancer patients treated with bevacizumab \[[@R44]\]. However, whether the use of EGFR-TKIs would increase the risk of infections in NSCLC remains undetermined.

A total of 17,420 NSCLC patients from 25 RCTs is included for analysis. As far as we known, our study is the first large meta-analysis to show a significantly increased risk of developing EGFR-TKIs related infection (Peto OR 1.48, p = 0.006) in NSCLC patients, but not for high-grade and fatal infectious events. Moreover, we perform a meta-regression analysis to assess the relationship between EGFR-TKIs treatment duration and risk of infections. The result shows that the peto OR of all-grade infections tends to be increased with EGFR-TKIs treatment duration, but it is not statistically significant (p = 0.26). As a result, clinicians should pay more attention to the risk of infections during the administration of EGFR-TKIs. Moreover, clinicians should treat NSCLC patients with any active infection before the initiation of EGFR-TKIs treatment.

Multiple mechanisms might involve in the development of infection. Basic research conducted by Lewkowicz et al \[[@R45]\] found TNF-α induced respiratory burst and phagocytic activity could be enhances by EGFR and its signal pathway. A recent study conducted by Li et al also demonstrated that EGFR play a critical role in the process of Tamm-Horsfall glycoprotein-enhanced neutrophil phagocytosis, and this effect could be suppressed by EGFR inhibitor \[[@R46]\]. However, more high-quality research are still recommended to determine the mechanisms of EGFR-TKIs associated infections.

Several limitations need to be mentioned in the present study. Firstly, as our study is a retrospective analysis of published studies, the baseline characteristics of each studies, such as dosage of EGFR-TKIs, periods of study conduct, and treatment regimens, might be potentially different, which might increase the heterogeneity among included studies. Second, we could not get individual patient data from each published studies, thus we could not perform a comprehensive analysis by adjusting baseline factors that existed between included trials.

CONCLUSIONS {#s4}
===========

In conclusion, our study has demonstrated that treatment with EGFR-TKIs in advanced NSCLC is associated with an increased risk of all-grade infections, but not for high-grade and fatal infections. Clinicians should be aware of these risks and provide regular follow-up for these toxicities.

MATERIALS AND METHODS {#s5}
=====================

Data sources {#s5_1}
------------

We performed this systematic review adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statements \[[@R47]\]. Our study was a meta-analysis of published data, and all of these included trials had been approved by the ethics committee, thus the ethical approval in our study was waved. To identify studies for inclusion in this study, we did a broad search of four databases, including Embase, Medline, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews, from the date of inception of every database to December 2015. Key words were "erlotinib", "gefitinib", "non-small-cell lung cancer", "lung carcinoma", "lung neoplasm", "randomized controlled trial" and "infections". The search was limited to prospective randomized clinical trials published in English. Each publication was reviewed and in cases of duplicate publications only the most complete, recent, and updated report of the clinical trial was included in the meta-analysis.

Study selection {#s5_2}
---------------

To be included for analysis in our systematic review and meta-analysis, the trials had to meet all the following criteria: 1) patients with pathologically confirmed non-small-cell lung cancer; 2) trials comparing therapy with or without EGFR-TKIs (erlotinib and gefitinib); 3) the included study had sufficient data for extraction. We assessed the quality of reports of clinical trials by using the 5-item Jadad scale including randomization, double-blinding, and withdrawals as previously described \[[@R48], [@R49]\].

Data extraction and clinical end point {#s5_3}
--------------------------------------

Two independent investigators reviewed the titles and abstracts of potentially relevant studies. We retrieved the full text of relevant studies for further review by the same two reviewers. A third senior investigator resolved any discrepancies between reviewers. If reviewers suspected an overlap of cohorts in a report, they contacted the corresponding author for clarification; we excluded studies with a clear overlap. We extracted the following data: first author's name, year of publication, number of enrolled subjects, treatment regimens, number of patients in treatment and controlled groups, median age, median treatment duration, median progression-free survival, median overall survival and adverse outcomes of interest (infections). The following adverse outcomes were considered as infectious events and were included in the analyses: Infections (not specified), febrile neutropenia, sepsis, septic shock, lung infection, respiratory tract infection and pneumonia. Adverse events of severe infections (≥grade 3), as assessed and recorded according to the National Cancer Institute's common terminology criteria (NCI-CTC, version 2 or 3; <http://ctep.cancer.gov>), were extracted for analysis, which has been widely used in cancer clinical trials.

Statistical analysis {#s5_4}
--------------------

Statistical analysis of the overall incidence and relative risk for all-grade, high-grade and fatal infections was calculated using comprehensive meta-analysis software version 2.0(Biostat, Englewood, NJ, USA). We used the Peto method to calculate ORs and 95% CIs because this method provided the best confidence interval coverage and was more powerful and relatively less biased than the fixed or random effects analysis when dealing with low event rates \[[@R50]\]. To calculate peto odds ratio (OR), patients assigned to EGFR-TKIs were compared only with those assigned to control treatment in the same trial. Additionally, to test whether effect sizes were moderated by differences in length of treatment, we carried out meta-regressions with difference in median length of experimental treatments (expressed in days) as predictor and relative risk as dependent variable. Between-study heterogeneity was estimated using the χ2-based Q statistic \[[@R51]\]. Heterogeneity was considered statistically significant when P heterogeneity \< 0.1. If heterogeneity existed, data was analyzed using a random effects model according to the method of DerSimonian and Laird \[[@R52]\]. In the absence of heterogeneity, the pooled estimate calculated on the basis of the fixed-effects model was reported using an inverse variance method. A statistical test with a p-value less than 0.05 was considered significant. The presence of publication bias was evaluated by using the Begg and Egger tests \[[@R53]\].
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